Redhill Biopharma Ltd.
RedHill Biopharma Ltd. focuses on gastrointestinal and infectious diseases. They develop and commercialize Talicia for H. pylori infection and Aemcolo for travelers diarrhea. Their pipeline includes five therapeutic candidates: opaganib, RHB-107, RHB-104, RHB-102, and RHB-204. These candidates are in clinical development for various indications. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -2,765% to -69% over the last 4 years, with operating losses in 4 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 36.4% of total assets.
Key Financial Data